Rein Therapeutics, Inc (RNTX)

In November 2025, the FDA lifted a clinical hold on the Phase 2 RENEW trial of LTI-03, increasing the stock price, but a subsequent publication led to a slight decline. In January 2026, Orphan Drug Designation from the European Medicines Agency for LTI-03 resulted in a minor stock price decrease. In March 2026, dosing the first patient in the Phase 2 trial of LTI-03 for IPF led to a stock price decrease. In April 2026, a clinical trial update for the Phase 2 RENEW study of LTI-03 was followed by a stock price decline. On April 30, 2026, the pricing of a $50 million public offering at $1.00 per share resulted in a significant stock price drop. Shareholder dilution has been a major risk, with total shares outstanding growing significantly.

As a clinical-stage biopharmaceutical company focused on research and development, Rein Therapeutics does not experience traditional product or service demand seasonality. The company's activities are concentrated on advancing its drug candidates through clinical trials.

Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for orphan pulmonary and fibrosis indications. The company operates in the Healthcare sector, specifically in the Biotechnology & Medical Research industry. Its lead product candidate, LTI-03, is in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and has received Orphan Drug Designation in the U.S. and Europe. LTI-01, a proenzyme, has completed Phase 1b and Phase 2a trials for loculated pleural effusion (LPE), but its development is delayed. LTI-05 is in preclinical trials for cystic fibrosis, and the company has other preclinical programs targeting cystic fibrosis and systemic fibrosis.

Rein Therapeutics, Inc. is headquartered in Austin, Texas, United States. Clinical trial sites for LTI-03 are active in the United States, Australia, and Poland, with plans to expand to the United Kingdom and Germany.

Rein Therapeutics' brand reputation is primarily tied to its scientific progress, clinical trial outcomes, and financial stability. Analyst sentiment is mixed, with some analysts having a "Strong Buy" rating, while others have a "Hold" consensus.

Rein Therapeutics Inc. has 52 institutional owners and shareholders holding a total of 10,947,576 shares. Major institutional owners include Voss Capital, LLC, BIOS Capital Management, LP, and Vanguard Group Inc. Key individual owners include CEO Brian Windsor and Muneer A. Satter, who owns a significant portion of the company's shares.